GEN Exclusives

More »

GEN News Highlights

More »
Oct 12, 2007

Sartorius Stedim Biotech and Greenovation Partner on Process-Scale Application of Moss-Based Protein Production Platform

  • Sartorius Stedim Biotech and greenovation Biotech will work on the process-scale implementation of the latter’s technology for producing complex proteins from moss cells called bryotechnology.

    The companies have been working together to develop fermentation processes in the field of bryotechnology. Yet, notes Hans-Peter Casel, managing director of Sartorius Stedim Systems, “The special requirements of the GMP environment pose real challenges to process-scale implementation of bryotechnology.”

    Sartorius Stedim Biotech says that it will now work on delivering the first GMP-compliant photobioreactor for bryotechnological applications within the next few months.

    Bryotechnology simplifies the process engineering involved with drug manufacturing, according to the firms.  Moss cells can be cultivated using relatively simple culture medium compositions, which reduce the complexity involved in controlling the process, they explain.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

The Triple Package and Success

One theory for explaining “success," put forward by Amy Chua Jed Rubenfeld, posits cultural traits such as a superiority complex, personal insecurity and impulse control. Union College professors Joshua Hart and Christopher Chabris counter that intelligence, conscientiousness, and economic advantage are the most likely elements of success, regardless of ethnicity. Do you think that Hart-Chabris make a better argument for achieving success than the Chua-Rubenfeld theory?

More »